33
Participants
Start Date
June 28, 2018
Primary Completion Date
November 11, 2021
Study Completion Date
November 11, 2021
Cetrelimab 480 mg
Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).
Apalutamide 240 mg
Apalutamide 240 mg (4\*60 mg) tablets per day will be administered orally.
Grand Hôpital de Charleroi, site Notre Dame, Charleroi
Hosp. Univ. Vall D Hebron, Barcelona
AZ Maria Middelares, Ghent
New York University Langone Medical Center, New York
Centers for Advanced Urology, LLC; d/b/a MidLantic Urology, Bala-Cynwyd
Thomas Jefferson University, Philadelphia
Istituto Europeo di Oncologia Servizio Radioterapia, Milan
Virginia Oncology Associates, Norfolk
Hosp. Gral. Univ. Gregorio Marañon, Madrid
Hosp. Univ. Ramon Y Cajal, Madrid
Hosp. Univ. Fund. Jimenez Diaz, Madrid
Hosp. Univ. Hm Sanchinarro, Madrid
Levine Cancer Institute, Carolinas HealthCare System, Charlotte
Hosp. Quiron Madrid Pozuelo, Pozuelo de Alarcón
Hosp. Virgen de La Victoria, Málaga
Hosp. Univ. Marques de Valdecilla, Santander
Instituto Valenciano de Oncologia, Valencia
Washington University, Bay Saint Louis
Regional Urology LLC, Shreveport
University of Texas, MD Anderson Cancer Center, Houston
Moscow City Clinical Hospital # 62, Moscow
Hertzen Oncology Research Institute, Moscow
Non-State Healthcare Institution 'Road Clinical Hospital of Russian Railways', Saint Petersburg
Russian Scientific Center of Radiology and Surgical Technologies, Saint Petersburg
Clinical Oncology Dispensary, Omsk
University of California San Francisco (UCSF) - Prostate Cancer Center, San Francisco
University of Michigan Health System, Ann Arbor
Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg, New York
Cross Cancer Institute, Edmonton
University of Toronto, Toronto
Centre de Recherche du CHUM, Montreal
NKI-AVL, Amsterdam, Amsterdam
UMC Radboud, Nijmegen
Sint Franciscus Gasthuis, Rotterdam
Janssen Research & Development, LLC
INDUSTRY